Tardive Dyskinesia Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023
Tardive Dyskinesia Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023
(EMAILWIRE.COM, November 22, 2017 ) Tardive dyskinesia is a movement disorder which develops with long duration compliance to antipsychotic drugs. This is characterised primarily by random movements of tongue, jaws, lips and different muscles sometimes even with fingers, toes and legs. In sever conditions of tardive dyskinesia patients may experience heaving breathing associated with trunk or hips or muscles swaying movements. It is a long-term cause of neuroleptic drugs which are more often prescribed for certain mental, neurological or GI disorders.
Growing prevalence of patients suffering from various neurological disorders is the major factor driving the market growth of TD treatment. For example, In 2017 April, Neurocrine Biosciences has published a report which stated that about 5lakhs people are suffering from TD in U.S. Tardive dyskinesia treatment market is anticipated to grow significantly during the forecast period owing to rise in geriatric population, busy and tense lifestyle, growing prescription of anti-psychotic drugs etc. The factors which are hampering the growth TD market is approval process of new treatment approaches by respective governments, delayed diagnosis of the disease and lack of awareness regarding the disease.
A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-tardive-dyskinesia-treatment-market/#ulp-4H8Z4LpNMLEuOnnx
The tardive dyskinesia treatment market is classified on the basis of drug class, infection type distribution channel, and geography.
Based on drug class, the tardive dyskinesia treatment market is segmented into the following
Beta blockers
Vitamin E systemic
VMAT2 inhibitors (vesicular monoamine transporter-2 inhibitors)
Dopaminergic agents
Benzodiazepines
Based on route of administration, the tardive dyskinesia treatment market is segmented into the following
Oral
Parenteral
Based on distribution channel, the tardive dyskinesia treatment market is segmented into the following
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-tardive-dyskinesia-treatment-market/#ulp-c654SbFYO64MsOhu
A variety of medicines are used to treat tardive dyskinesia such as clonidine etc. Botox injections can be given for minor TD. Vitamin B6, vitamin E and branched chain amino acids are helpful in minimizing the symptoms of tardive dyskinesia. Benzodiazepines therapy is the most effective therapy for tardive dyskinesia. However, the development of tolerance is restraining its growth in the market. Tevas AUSTEDO was approved for the treatment of chorea associated with tardive dyskinesia. Austedo is likely to create competition for INGREZZA of Neurocrine Biosciences.
Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/global-tardive-dyskinesia-treatment-market/#ulp-14mlyhjMGhVjZqa3
On the basis of Geographical regions, Global tardive dyskinesia treatment market is classified as into five key regions as Europe, Asia- Pacific, North America, Middle East & Africa and Latin America. North America is the dominating market in tardive dyskinesia owing to the development of new drugs, growing prevalence of tardive dyskinesia, rising investments on R&D investments. Europe and Asia Pacific are also expected to have significant growth rate due to the growing investments, rising awareness and rise in disposable income of the emerging countries.
Some of the players in global tardive dyskinesia treatment market are Biogen (U.S), Teva Pharmaceutical Industries Ltd. (Israel), GlaxoSmithKline Plc.(U.K), Johnson & Johnson Services, Inc.(U.S), Pfizer Inc.(U.S), Neurocrine Biosciences, Inc.(U.S), Novartis AG(Switzerland), AstraZeneca (U.K), Bayer AG (Germany) and Sanofi (France).
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com
Growing prevalence of patients suffering from various neurological disorders is the major factor driving the market growth of TD treatment. For example, In 2017 April, Neurocrine Biosciences has published a report which stated that about 5lakhs people are suffering from TD in U.S. Tardive dyskinesia treatment market is anticipated to grow significantly during the forecast period owing to rise in geriatric population, busy and tense lifestyle, growing prescription of anti-psychotic drugs etc. The factors which are hampering the growth TD market is approval process of new treatment approaches by respective governments, delayed diagnosis of the disease and lack of awareness regarding the disease.
A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-tardive-dyskinesia-treatment-market/#ulp-4H8Z4LpNMLEuOnnx
The tardive dyskinesia treatment market is classified on the basis of drug class, infection type distribution channel, and geography.
Based on drug class, the tardive dyskinesia treatment market is segmented into the following
Beta blockers
Vitamin E systemic
VMAT2 inhibitors (vesicular monoamine transporter-2 inhibitors)
Dopaminergic agents
Benzodiazepines
Based on route of administration, the tardive dyskinesia treatment market is segmented into the following
Oral
Parenteral
Based on distribution channel, the tardive dyskinesia treatment market is segmented into the following
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-tardive-dyskinesia-treatment-market/#ulp-c654SbFYO64MsOhu
A variety of medicines are used to treat tardive dyskinesia such as clonidine etc. Botox injections can be given for minor TD. Vitamin B6, vitamin E and branched chain amino acids are helpful in minimizing the symptoms of tardive dyskinesia. Benzodiazepines therapy is the most effective therapy for tardive dyskinesia. However, the development of tolerance is restraining its growth in the market. Tevas AUSTEDO was approved for the treatment of chorea associated with tardive dyskinesia. Austedo is likely to create competition for INGREZZA of Neurocrine Biosciences.
Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/global-tardive-dyskinesia-treatment-market/#ulp-14mlyhjMGhVjZqa3
On the basis of Geographical regions, Global tardive dyskinesia treatment market is classified as into five key regions as Europe, Asia- Pacific, North America, Middle East & Africa and Latin America. North America is the dominating market in tardive dyskinesia owing to the development of new drugs, growing prevalence of tardive dyskinesia, rising investments on R&D investments. Europe and Asia Pacific are also expected to have significant growth rate due to the growing investments, rising awareness and rise in disposable income of the emerging countries.
Some of the players in global tardive dyskinesia treatment market are Biogen (U.S), Teva Pharmaceutical Industries Ltd. (Israel), GlaxoSmithKline Plc.(U.K), Johnson & Johnson Services, Inc.(U.S), Pfizer Inc.(U.S), Neurocrine Biosciences, Inc.(U.S), Novartis AG(Switzerland), AstraZeneca (U.K), Bayer AG (Germany) and Sanofi (France).
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com
Contact Information:
Precision Business Insights
Sales
Tel: +1-866-598-1553
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Precision Business Insights
Sales
Tel: +1-866-598-1553
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results